ucsf logo

New ways to tackle cancer-causing virus, eye disease win CTSI funding awards

A promising new way to fight human herpes viruses and a drug delivery device to better treat a major cause of blindness have won development funding from UCSF’s Clinical and Translational Science Institute (CTSI).

The herpes virus treatment project, awarded $100,000 under CTSI’s T1 Translational Catalyst Awards, is led by Charles Craik, PhD, a faculty member in the UCSF School of Pharmacy’s Department of Pharmaceutical Chemistry. One of the project’s prime targets is the virus that causes the most common HIV/AIDS-associated cancer.

The development of the device to treat eye disease, which was awarded $85,000, is led by Tejal Desai, PhD, a faculty member in the Department of Bioengineering and Therapeutic Sciences, a joint department of the UCSF Schools of Pharmacy and Medicine.

The T1 Awards, which are offered twice a year, are designed to help drive promising early-stage research through the process of translating ideas into therapies that benefit patients. In addition to funding, they provide customized expert feedback and advice.

Morehttp://pharmacy.ucsf.edu/news/2012/08/31/1/

Tags: 
CTSI
Clinical and Translational Science Institute
T1
Translational Catalyst Awards
herpes virus
drug delivery device
dimer disrupter 2
DD2
allosteric regulation
cytomegalovirus
CMV
Kaposi’s sarcoma-associated herpes virus
KSHV
Small Molecule Discovery Center
age-related macular degeneration
AMD
National Eye Institute
National Institutes of Health
Key people: 
Charles Craik
Tejal Desai
Adam Renslo
Jonathan Gable
Gregory Lee

Next topic: About QBC